Questcor's cash, cash equivalents and short-term investments totaled approximately $71 million, and accounts receivable totaled $11 million. During the third quarter, the Company did not repurchase any shares of its common stock. Prior …
Questcor Pharmaceuticals Inc (NASDAQ:QCOR) has been a battleground stock for years. Bulls have stood by the strong financial performance of the company, while bears have been clinging to the threat of multiple government investigations …
The 16% price increase comes on the news that Questcor is being acquired by an Irish specialty-pharmaceutical company, Mallinckrodt, in a deal worth $5.6 billion in cash and stock. It is worth noting, as always in these cases, that …
Shares of Questcor originally leaped over the 27% premium Mallinckrodt is paying, but the stock has pulled back some. Questcor is something of a one-trick pony. But it is a big trick. The company’s H.P. Acthar injectable gel has been …
As a result of defendants’ false statements, Questcor’s stock traded at artificially inflated prices during the Class …
Questcor’s shares were trading at $77 on the Nasdaq on Monday afternoon. Mallinckrodt was down 6 percent at $58.50 on the New York Stock Exchange. The deal - the latest in a series of acquisitions structured to take advantage of Ireland’s …
In a report published Tuesday, Mizuho Securities USA analyst Mario Corso reiterated a Buy rating and $93.00 price target on Questcor Pharmaceuticals (NASDAQ: QCOR). In the report, Mizuho Securities USA noted, “In the wake of today's …
Questcor's stock leapt nearly 40% during trading yesterday as investors welcomed its $135m-plus purchase of Novartis' rival immune drug Synacthen. The US speciality pharma said it has bought rights to develop Synacthen (tetracosactide) …
Questcor shareholders will receive $30.00 per share in cash and 0.897 Mallinckrodt shares for each share of Questcor common stock they own, for a total approximate consideration of $86.10 per Questcor share. Following completion of …
Questcor’s shares were trading at $77 on the Nasdaq on Monday afternoon. Mallinckrodt was down 6 percent at $58.50 on the New York Stock Exchange. The deal - the latest in a series of acquisitions structured to take advantage of Ireland’s …